


# Early tumor progression during first-line immunotherapy treatment

## Clinical Case Study



**STAGE IV NSCLC PATIENT**

**Age:** 65

**Medical history:** Non-smoker, otherwise healthy

**Mutation status:** No driver mutations

**PD-L1 expression:** 30%



**Presentation**

- Patient complained of a persistent cough
- Evaluation revealed a 3.4 cm mass in the left lower lobe and several small liver nodules
- ECOG PS: 1



**Diagnosis**

Advanced NSCLC with liver metastases



**Treatment**

Pembrolizumab (2 mg/kg q3w) was chosen as first-line therapy due to hesitancy of patient to start chemotherapy and low tumor burden, with plans to add on chemotherapy if patient isn't responding well



**Pathology**


- Adenocarcinoma
- Tumor was negative for *EGFR*, *ROS1*, *RET*, *BRAF*, *HER2*, and *NTRK*, and immunohistochemistry showed no *ALK* rearrangements
- PD-L1 expression: 30%
- Normal creatinine levels and liver function



**What solid tumor types would you start with single-agent immunotherapy and escalate to combination therapy after determining early non-response?**

# Signatera ctDNA can help with decisions on changes in therapy approach

**What types of patients might you start with single-agent immunotherapy, and wait to decide whether to add another therapy?**



In what types of patients would you consider initiating front-line treatment with single-agent immunotherapy?

What clinical factors do you currently use to evaluate when a switch from single-agent immunotherapy to combination therapy is needed?

## Patient perspective

The patient opted to initiate with single-agent immunotherapy at diagnosis due to concerns with chemotherapy toxicities. Rising Signatera ctDNA results convinced him that adding chemotherapy will give him the best chance at stabilizing the disease.

## Key takeaway

Use Signatera ctDNA results to evaluate early response or non-response to single-agent immunotherapy approaches, and determine whether to pivot to a combination therapy approach.



*Because of Signatera, I can put cancer in a box on a shelf with confidence and live in three month intervals between scans with more confidence.*  
LUANN, PATIENT

**Learn more at [nateraoncology.com](http://nateraoncology.com)**